WP9 - Dissemination, communication, and patient advocacy

Amplifying impact through transparent outreach and stakeholder collaboration

To share EASYGEN’s findings with scientific, clinical, and public audiences the team develops a dynamic dissemination and communication strategy – featuring a unified brand identity, website, social media presence and toolkit for presentations and press releases. It conducts a literature review on CAR-T patient quality of life (QoL), including a patient questionnaire to assess patient-reported burden to access CAR-T cell therapy, to inform targeted messaging and convenes roundtable workshops with patient advocacy groups to co-create educational resources and a white paper on lived-experience insights. Ongoing stakeholder networking ensures that healthcare providers and patients are actively engaged throughout the project’s lifespan.

Led by
Fresenius SE & Co. KGaA
and:
Fresenius logo
EBMT logo
quironsalud logo
Helios Klinikum Berlin-Buch logo
Universidad De Navarra logo
Bar Ilan University logo
Cellix logo
Charles River logo
Danmarks Tekniske Universitet logo
Frankfurt School Of Finance & Management logo
Fraunhofer IZI logo
Fraunhofer IESE logo
Fresenius Kabi logo
Helmholtz-Zentrum Dresden-Rossendorf logo
Philips Electronics Nederland logo
PRO-LIANCE GLOBAL SOLUTIONS logo
TQ Therapeutics logo
University Of Glasgow logo
See all work packages